Nuvectis Pharma, Inc. (NASDAQ:NVCT) Major Shareholder Marlio Charles Mosseri Buys 21,167 Shares

Nuvectis Pharma, Inc. (NASDAQ:NVCT) major shareholder Marlio Charles Mosseri purchased 21,167 shares of the business’s stock in a transaction dated Monday, May 12th. The shares were purchased at an average cost of $8.11 per share, with a total value of $171,664.37. Following the purchase, the insider now directly owns 2,942,761 shares in the company, valued at approximately $23,865,791.71. The trade was a 0.72% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Large shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

Marlio Charles Mosseri also recently made the following trade(s):

• On Thursday, May 8th, Marlio Charles Mosseri bought 2,650 shares of Nuvectis Pharma stock. The stock was purchased at an average cost of $8.65 per share, with a total value of $22,922.50.
• On Tuesday, May 6th, Marlio Charles Mosseri purchased 12,444 shares of Nuvectis Pharma stock. The stock was acquired at an average price of $8.59 per share, with a total value of $106,893.96.

Nuvectis Pharma Stock Performance

Shares of NASDAQ NVCT opened at $8.43 on Wednesday. The firm has a market cap of $199.24 million, a price-to-earnings ratio of -7.27 and a beta of -0.11. The business’s 50-day simple moving average is $9.03 and its 200-day simple moving average is $7.20. Nuvectis Pharma, Inc. has a 52 week low of $4.44 and a 52 week high of $11.80.

Nuvectis Pharma (NASDAQ:NVCT) last announced its quarterly earnings data on Tuesday, May 6th. The company reported ($0.27) EPS for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.03. As a group, equities research analysts forecast that Nuvectis Pharma, Inc. will post -1.01 earnings per share for the current year.

Institutional Investors Weigh In On Nuvectis Pharma

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Cubist Systematic Strategies LLC acquired a new stake in shares of Nuvectis Pharma during the fourth quarter worth $34,000. Blue Zone Wealth Advisors LLC acquired a new stake in shares of Nuvectis Pharma during the first quarter worth $102,000. Nations Financial Group Inc. IA ADV grew its stake in shares of Nuvectis Pharma by 35.0% during the fourth quarter. Nations Financial Group Inc. IA ADV now owns 13,500 shares of the company’s stock worth $73,000 after purchasing an additional 3,500 shares during the period. Baxter Bros Inc. grew its stake in shares of Nuvectis Pharma by 20.0% during the fourth quarter. Baxter Bros Inc. now owns 15,000 shares of the company’s stock worth $81,000 after purchasing an additional 2,500 shares during the period. Finally, Squarepoint Ops LLC acquired a new stake in shares of Nuvectis Pharma during the fourth quarter worth $103,000. 96.77% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities analysts recently commented on the company. HC Wainwright reissued a “buy” rating and set a $15.00 price target (up from $11.00) on shares of Nuvectis Pharma in a research report on Wednesday, April 30th. Maxim Group started coverage on Nuvectis Pharma in a research report on Wednesday, April 2nd. They set a “buy” rating and a $17.00 price target on the stock. Finally, Laidlaw started coverage on Nuvectis Pharma in a research note on Monday, March 17th. They set a “buy” rating and a $19.00 price objective for the company.

Nuvectis Pharma Company Profile

Nuvectis Pharma, Inc, a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma.